Endocrine Abstracts

Introduction: One of the most promising potential targets for new treatments in Graves ophthalmopathy (GO) is the insulin-like growth factor 1 receptor (IGF1R). However, a significant impediment to the translational pathway in developing new treatments for GO is the lack of any animal or in vitro model.Aims: To characterise dysregulation of IGF1 pathway related gene expression in GO. To develop a new in vitro model for tissue expansion in G...

Graves’ orbitopathy affects approximately 0.25 million people in the UK and is associated with a significant psychological and socioeconomic burden. Surveys have illustrated that Graves’ orbitopathy is often treated inadequately. The Amsterdam Declaration is a recent incentive supported by many national and international professional and patient-led organizations including the SfE, aiming to improve the outcomes of patients with Graves’ orbitopathy. This report ...